Peptide Regulation Showdown: PCAC Vote Outcome
Key Questions
What was the result of the FDA PCAC committee vote on peptides?
The committee voted to recommend BPC-157, KPV, TB-500, MOTs-C, Semax, and Epitalon for the 503A bulks list, overriding FDA staff opposition, while excluding DSIP. The vote is non-binding and will be followed by public rulemaking.
Which peptides were included in the PCAC recommendations?
BPC-157, KPV, TB-500, MOTs-C, Semax, and Epitalon received recommendations for inclusion on the 503A bulks list. DSIP was the only peptide explicitly excluded from the list.
How might this vote impact the peptide industry?
Industry insiders and telehealth providers could gain $2-3 billion from expanded access, amid ongoing gray market demand and consolidation involving firms like Samsung and PolyPeptide. Lawsuits related to peptide regulation are also expected to continue.
What political dynamics influenced the PCAC vote?
A split emerged between Kennedy appointees and career FDA scientists, with the committee overriding staff opposition in a non-binding decision. This reflects broader tensions in peptide policy review.
What are the next steps following the PCAC vote?
The non-binding vote will proceed to public rulemaking by the FDA. Related articles note that advisers recommended relaxing compounding rules for these unapproved peptides.
FDA PCAC committee voted to recommend BPC-157, KPV, TB-500, MOTs-C, Semax, and Epitalon for 503A bulks list, overriding FDA staff opposition; DSIP excluded. Non-binding vote; public rulemaking ahead. Political split between Kennedy appointees and career scientists. Industry insiders and telehealth stand to gain $2-3B. Gray market demand, industry consolidation (Samsung/PolyPeptide), and lawsuits continue.